(PHOENIX, Ariz. – Feb. 17, 2022) –Dignity Health in Arizona is launching the first research study in North America in which genetic testing is used to identify men and women at risk of developing heart disease based on the makeup of their DNA. If proven effective in clinical trials, this form of genetic testing may be adopted globally to prevent heart disease. Heart disease is the No. 1 killer in the world – in fact, half of Americans are expected to have at least one cardiac event in their lifetime. Continue reading
February 2, 2022 – A new treatment for autism, created by Arizona State University researchers and their colleagues, has been granted a patent by the U.S. Patent Office. Continue reading
Statement from Critical Path Institute Board Chair Wainwright Fishburn on the Senate Confirmation of Dr. Robert M. Califf, MD, MACC, as Commissioner of the U.S. Food and Drug Administration (FDA), Feb. 15, 2022.Continue reading
AZBio President & CEO, Joan Koerber-Walker, shared insights with Duane Schulthess, Managing Director of Vital Transformation on the the Vital Health Podcast. The popular podcast series has a global reach and features relaxed, one on one discussion with health care professionals, researchers, and regulators. Topics explore the implications of new medical procedures, technologies and policies as well as their impact on current clinical practices.
New Senior Members’ inventions range from a beating heart patch to optical devices that have enabled the modern internetContinue reading
Members of the Arizona bioscience and healthcare community work every day to discover, develop, and deliver life changing and live saving solutions. Now, one Arizona life science leader aspires to take what he has learned as a bioscience company co-founder and CEO and use it to build solutions as an Arizona State Senator. Meet David W. Richardson.
Researchers will Study How Drug Used to Lower Blood Pressure can Change Fibroblasts to Provide Long-Lasting Protection for the HeartContinue reading
OncoMyx Therapeutics and Avery Therapeutics will be presenting at BIO CEO.Continue reading
“Starting up NeuTherapeutics is so exciting because we are creating the path to bring the first regenerative therapeutic for Alzheimer’s disease to those who need it. We believe that treatment with allo will restore brain function and independence for patients,” says Dr. Roberta Brinton, a Regents Professor of pharmacology and neurology and a member of the BIO5 Institute.